drugset / Trial / NCT07632846

Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis

NCT07632846

Phase 2 Recruiting 50 enrolled Horus University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Rheumatoid arthritis is a chronic inflammatory disease that causes joint pain, swelling, and reduced physical function. Although standard disease-modifying antirheumatic drugs are effective for many patients, some individuals continue to have active disease. The purpose of this study is to evaluate the effectiveness and safety of adding roflumilast to standard therapy in patients with active rheumatoid arthritis. Participants will receive either roflumilast or placebo in addition to their usual treatment. The study will assess changes in disease activity and inflammatory markers over a follow-up period of approximately 12 weeks. The results of this study may help determine whether roflumilast could be a useful add-on treatment option for patients with rheumatoid arthritis.

Timeline

Start
2026-05-19
Primary completion
2026-10
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 500 ug Oral

Indications